Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter and Year ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals has submitted a routine compliance certificate to BSE for the quarter ended March 31, 2025, as required under SEBI's Depositories and Participants Regulations. The certificate, issued by the company's Registrar and Share Transfer Agent (CIL Securities Limited), confirms that all share dematerialisation requests received from depository participants during the January–March 2025 quarter were properly processed. It also confirms that the physical share certificates received were mutilated and cancelled, and the depositories' names were updated as the registered owners in the company's Register of Members within the stipulated time. This is a standard quarterly regulatory submission with no business or financial numbers involved.
No impact on shareholders or stock price — this is a routine administrative filing confirming that share transfer and dematerialisation processes were handled correctly during the quarter.